Monthly NfL monitoring for relapsing-remitting MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether monthly blood tests for a nerve protein (NfL) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (RRMS) who are on certain first-line treatments. It aims to find out if this monitoring helps catch early signs of active disease before symptoms appear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsing-remitting MS (RRMS) diagnosed within the last 10 years using the 2024 McDonald criteria.
- You've had signs of active MS in the last 2 years (a relapse, new or enlarging brain lesions on MRI).
- You are currently taking a standard first-line MS drug (such as interferon, glatiramer acetate, teriflunomide, or fumarates) and have been on it for less than 2 years.
- You have had a routine MRI within the last 3 months and are stable (no relapse in the last month).
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the trial if you could become pregnant.
- You are willing to have monthly blood draws and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether MS relapses happen without any signs of new disease activity on an MRI scan. By tracking your symptoms and scans, researchers hope to better understand how MS affects people in real life. If you qualify, you may help improve future treatment decisions.
This study follows adults with relapsing-remitting multiple sclerosis using MRI scans and blood tests. It aims to understand how the disease behaves and what markers in blood and imaging may relate to changes over time.
This trial uses MRI scans to monitor spinal cord changes in people newly diagnosed with relapsing-remitting MS who have not yet started treatment. It aims to better understand how the disease progresses and could help guide early treatment decisions.
This study is a long-term observational study—it does not test a new drug but follows people with certain nerve and immune conditions (like multiple sclerosis, myasthenia gravis, and others) to learn more about how these diseases progress. By joining, you help researchers gather valuable data that could improve care for others with similar conditions.
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.